AUSTIN, Texas (April XX, 2021) — SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., president CEO of BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX-V: BCT) (“the Company”), to discuss the Company’s targeted immunotherapies for breast cancer and its unique position as a clinical-stage biotech with proof-of-concept data for its lead asset.
BriaCell develops novel therapies for the safe and targeted management of cancer. Speaking with SCV’s Stuart Smith, Dr. Williams discusses BriaCell’s drug pipeline, highlighting lead candidate Bria-IMT™ for advanced breast cancer.
As the second-leading cause of cancer in women, breast cancer kills 43,000 women in the U.S. each year. With Bria-IMT, BriaCell sees the potential to change these statistics; Bria-IMT has achieved positive proof-of-concept (POC) in three clinical trials, where it improved the survival rate of women with advanced-stage breast cancer by over a year.
While the positive data was an obvious win for BriaCell in 2020, the year also delivered challenges. Dr. Williams describes how he and the Company’s board of directors and advisors were able to lead BriaCell through the hardships of the COVID pandemic.
“We had a very difficult year in 2020, but because of our perseverance and our belief in our technology and the exciting clinical results we’ve obtained, as well as our very deep and diversified pipeline, we decided to hang in there,” he says. “Now we’re getting the trains running again. We’re very excited that we’re in a position to really make a major contribution in the area of breast cancer and all cancers in general.”